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Rheumatoid Arthritis (RA) is common in the reproductive age. Women with RA have an impaired fertility
related to the use of certain medication and active disease. RA usually improves during pregnancy, however
almost half of the patients still have active disease in third trimester. Pregnancy outcomes are slightly less
favorable, especially in women with high disease activity. Managing RA during pregnancy is challenging,
because treatment options are limited. Accumulating evidence shows the safety of Tumor Necrosis Factor
inhibitors in pregnant RA patients and patients with a wish to conceive.
This paper reviews the current perspective on fertility, pregnancy and childbirth in women with RA and dis-
cusses treatment options before and during pregnancy.
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Rheumatoid Arthritis (RA) is one of the most common chronic dis-
eases in women in their reproductive age. For women with RA it is
harder to achieve parenthood. This is related to the disease itself and
the use of medication [13].
Treating RA before and during pregnancy can be challenging since
some drugs are considered teratogenic and active disease is associ-
ated with adverse fertility and pregnancy outcomes. Disease activity
improves during pregnancy, but less than previously anticipated [4].
A signiﬁcant number of patients has active disease and the use of
anti-rheumatic drugs is still required. Information on the safety of
medication during pregnancy, especially information on Tumor
Necrosis Factor Inhibitors (TNF), is accumulating. Therefore more
treatment options are available before and during pregnancy than
previously considered.Fertility
For women with RA it is harder to conceive a child. Multiple stud-
ies show that family size is reduced in women with RA and this may
already be present before their diagnosis of RA [2]. Time to pregnancy
(TTP) is a reliable way to measure fertility. A TTP greater than 12
months is considered as subfertility. In the general population the
median percentage of subfertility is 9%, for RA patients this percent-
age is 2542% [1,2].Several factors are thought to contribute to the impaired fertility
in RA patients. Some anti-rheumatic drugs have been associated with
impaired fertility outcomes. Non-steroidal anti-inﬂammatory drugs
(NSAIDs) and high doses of prednisone (>7.5mg daily) prolong the
TTP [1]. For NSAIDs, the inhibition of the production of prostaglan-
dins which play a role in ovulation and implantation, is most likely to
be responsible. The negative effect of prednisone on fertility could be
related to a direct effect on the endometrium and ovary and/or sup-
pression of the hypothalamic-pituitary-ovarian axis [2,3]. Less is
known on beneﬁcial effects of anti-rheumatic drugs on fertility. A
small retrospective study showed that in RA patients with a wish to
conceive, treatment with biologic disease-modifying anti-rheumatic
drugs (bDMARD) at the time of conception could shorten the TTP [5].
Active disease is associated with subfertility. In a large prospective
cohort on RA and pregnancy, a TTP > 1 year was found in 67% of
women with high disease (DAS28-CRP > 5.1). Whereas for women in
remission (DAS28-CRP  2.6) a TTP > 1 year was found in only 30% of
the study cases [1].
Earlier menopause has been observed in RA patients. Therefore, it
has been hypothesized that RA patients have a smaller ovarian
reserve. The most reliable marker for ovarian reserve is anti-
M€ullerian hormone (AMH). In patients with early RA no differences
in serum AMH were found compared to healthy controls [6]. In
patients with established RA decreased levels of serum AMH are
found, however this was not associated with TTP [7]. These results
imply a role of the disease or medication use in the decreased levels
of serum AMH. Sexual problems are common in RA and therefore a
lower intercourse frequency might partially account for the subfertil-
ity [2,3]. It should be noted that studies on this topic are not
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smaller family size in RA patients might reﬂect personal choices
related to chronic disease [2].
At fertility work-up in 41% of sub fertile RA patients no cause for
the subfertility can be identiﬁed, compared to 828% in the general
population. Indicating that disease related factors contribute to the
prolonged TTP in RA patients [8].
As a result of impaired fertility rates, RA patients are more likely
to receive fertility treatment . Assisted reproductive technology
(ART) was found safe and effective in one study [8]. However, data
from the nationwide Danish Health Registries showed a reduced
chance of a live birth in women with RA receiving ART compared to a
healthy reference group. The authors suggested that this was related
to an impaired chance of embryo implantation. In their study, the use
of prednisone before conception increased the odds ratio for live
birth [9]. The reason for this is unknown.
Pregnancy
Disease activity improves during pregnancy, a recent systematic
review and meta-analyses by Jethwa et al. found a combined
improvement rate of RA during pregnancy of 60%. The authors found
a combined ﬂare rate post-partum of 46.7% [10]. Furthermore, the
ﬂare in disease activity has been described after a miscarriage [2,3].
The improvement rates in older studies are much higher; 7595%
[2]. In contrast to the recent prospective studies, the older studies
used self-reported measures for disease activity, disease activity was
often scored retrospectively and these studies were of smaller sample
size. In addition, in these older studies various deﬁnitions of disease
activity were used and patients were not seen before conception.
Management of RA has improved in the last 25 years with the intro-
duction of a treat-to-target approach and new and effective treat-
ment options. This resulted in women entering pregnancy with
lower disease activity and therefore the potential to improve in dis-
ease activity was decreased [2,3].
Rheumatoid factor (RF) and Anti-citrullinated protein antibody
(ACPA) serum levels are not inﬂuenced by pregnancy. However, RF
and/or ACPA status has an effect on the spontaneous improvement
during pregnancy [11]. Patients without these antibodies are more
likely to improve than patients with antibodies. Another study
showed that disease activity itself is a clinical feature associated with
the disease course of RA during pregnancy: RA patients in low disease
activity in the ﬁrst trimester are likely to have low disease activity or
remission in the last trimester [12].
Pregnancy outcomes
Data on pregnancy outcomes in RA patients are well documented
and reported in previous literature [2,3]. Compared to the general
population, pregnancy outcomes in RA patients are slightly less
favorable and related to active disease. In patients with well-regu-
lated disease pregnancy outcomes are comparable to the general
population [4,13].
Hypertensive disorders and preeclampsia are more common in
women with RA compared to the general population . Data from the
Norwegian birth registry showed that the risk of preeclampsia in RA
patients is 5.0% compared to 3.4% in unaffected women [2]. Women
with RA have an increased risk of small for gestational age (SGA)
infants and intrauterine growth restriction (IUGR). The risk of SGA is
10%, compared to 3% in the general population. Increased disease
activity is an independent risk-factor for lower birthweight among
newborns in RA patients. The risk of IUGR is almost doubled for RA
patients compared to the general population (odds ratio (OR) 1.93,
95% Conﬁdence interval (CI) 1.812.05) [2,3,13].
Pregnant RA patients have an increased risk for preterm delivery
(PTD) (deﬁned as birth before 37 weeks of gestational age) . Thisincreased risk is 915% compared to 68% in the healthy population.
Risk factors for PTD are the use of prednisone during pregnancy and
the severity of the disease. The risk of premature rupture of mem-
branes (PROM) (OR 1.548, 95% CI 1.4741.626) and antepartum hem-
orrhage were found slightly elevated in RA patients (OR 1.229, CI
1.1521.312) [2,3,13].
RA patients have an increased risk of cesarean delivery. This
increased risk is associated with disease activity. In the PARA cohort,
the cesarean section rate was 22% for the active disease group
(DAS28-CRP > 3.2) and 10% in the group with DAS28-CRP  3.2 [4].
The risk of miscarriages might be increased in women with RA.
One study did not show an increased risk of miscarriages, however
data from the Norwegian birth registry showed that RA patients have
an increased risk of miscarriage (OR 1.32, CI 1.191.47) [2]. It should
be noted that this study included both planned and unplanned preg-
nancies. Many of the unplanned pregnancies will therefore be con-
ceived whilst taking methotrexate (MTX). MTX induces miscarriages
and therefore the risk of miscarriages might be overestimated. Infor-
mation on medication was not available in this study.
Offspring of RA patients
Offspring of RA patients do not have an increased risk on mayor
congenital malformations. Long-term follow-up of offspring of RA
patients revealed no differences in anthropometric measurements
compared to children born to healthy mothers [2,3].
Medication during pregnancy and lactation period
Treatment algorithms with conventional and biologic disease
modifying drugs, applying a treat-to-target approach have resulted
in better outcomes for RA patients. However, applying a treat-to-tar-
get approach in pregnancy can be challenging; because of a lack of
safety data not every treatment option is compatible with pregnancy.
An overview of the safety of anti-rheumatic drugs during pregnancy
and breastfeeding is given in Table 1.
Conventional disease modifying anti-rheumatic drugs (cDMARD),
NSAIDs and glucocorticoids
In 2016, a European League Against Rheumatism (EULAR) task-
force published points to consider for use of anti-rheumatic drugs in
the preconception period, pregnancy and postpartum [14].
Sulfasalazine (SSZ) (in a daily dose up to 2000mg) and Hydroxy-
chloroquine (HCQ) (in a daily dose 200mg400mg) are considered
safe to use during pregnancy. Azathioprine and Cyclosporine too, are
proven to be safe for the use during pregnancy. MTX and Leﬂunomide
should be avoided before and during pregnancy [14].
The use of NSAIDs is associated with impaired fertility outcomes;
the TTP is prolonged when taking NSAIDs. NSAIDs could be prescribed
during the 1st and 2nd trimester, however impaired renal function of
the child and oligohydramnios have been described. It is advised to
stop NSAIDs during the 3rd trimester because they can impair labor
and cause premature constriction of the ductus arteriosus [2].
Prednisone is largelymetabolized by the placenta. The use and period
of prednisone before and during pregnancy should be limited however.
Prednisone use is associated with preterm delivery [15] and high dose
prednisone use (>7.5 g daily dose) is associated with prolonged TTP [1].
Prednisone use is associated with IUGR and PROM too [2,3].
Biologic disease modifying anti-rheumatic drugs (bDMARD)
TNF inhibitors are the best-studied biologic agents during
pregnancy and safety data on TNF inhibitors during pregnancy is
reassuring.
Table 1
Anti-rheumatic drugs and their compatibility during pregnancy and breastfeeding [14].
Medication Pregnancy Lactation
Hydroxychloroquine No increased risk on congenital malformations, may
be used throughout pregnancy
Safe during lactation period
Sulfasalazine No increased risk on congenital malformations, may
be used throughout pregnancy up to 2000mg daily
with folate supplementation
Safe during lactation period in healthy babies
Glucocorticoids No increased risk on congenital malformations, may
be used throughout pregnancy at lowest possible
dose. Prednisone use is associated with preterm
delivery [15] and high dose prednisone (>7.5 g
daily dose) use is associated with a prolonged time
to pregnancy [1].
Safe during lactation period
Methotrexate Proven teratogenic. Not recommended for use during
pregnancy. Must be stopped 13 months before
planned pregnancy
Should be avoided during lactation period
Leﬂunomide May be teratogenic, insufﬁcient data available. Not
recommended for use during pregnancy. Washout
period with Cholestyramine is recommended
before pregnancy
Insufﬁcient data available, should be avoided during
lactation period
NSAIDs No increased risk on congenital malformations.
Should be stopped in third trimester of pregnancy
Safe during lactation period
Certolizumab No increased risk on congenital malformations, may
be used throughout pregnancy
Safe during lactation period
Inﬂiximab No increased risk on congenital malformations.
Advised to be stopped before 20th week of
pregnancy
Safe during lactation period
Adalimumab No increased risk on congenital malformations.
Advised to be stopped before 20th week of
pregnancy
Safe during lactation period
Etanercept No increased risk on congenital malformations.
Advised to be stopped before 32nd week of
pregnancy
Safe during lactation period
Golimumab No increased risk on congenital malformations, insuf-
ﬁcient data available. Not recommended for use
during pregnancy
Safety data is scarce, expert consensus is that it is safe
during lactation period
Other biologicals (Rituximab, Anakinra,
Ustekinumab, Tocilizumab)
No increased risk on congenital malformations (Rit-
uximab, Anakinra, Ustekinumab), insufﬁcient data
available. Not recommended for use during
pregnancy
Insufﬁcient data available, should be avoided during
lactation period
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Golimumab are entire monoclonal IgG1 antibodies, Etanercept only
contains a part of the Fc-region of IgG1 and Certolizumab is a PEGy-
lated fragment antigen-binding (Fab) and contains no Fc region [14].
Active transport of TNF inhibitors over the placenta into the fetal cir-
culation is mediated through binding to the fetal Fc receptor and
occurs as early as week 18 of gestation. Adalimumab and Inﬂiximab
have high afﬁnity for the fetal Fc receptor, Etanercept binds weakly
to this receptor and Certolizumab does not bind to this receptor at all
since it does not contain a Fc-region. Hence the level of TNF inhibitor
that can be detected in the cord blood is associated with the type of
TNF inhibitor [14]. In addition, placental transfer increases over time
and therefore the timing of administration during pregnancy is asso-
ciated with the level of TNF inhibitor that can be detected in the cord
blood. The lowest levels of anti-TNF in the cord blood are observed
for Certolizumab and Etanercept. Exposure to Inﬂiximab and Adali-
mumab, especially later in pregnancy, results in higher levels of the
drug detectable in the umbilical cord blood compared to Etanercept
and Certolizumab. Both Inﬂiximab and Adalimumab can be detected
in the fetal circulation up to one year for Inﬂiximab and up to 9
months for Adalimumab [16].
The best timing to stop anti-TNF treatment, so that no levels of
TNF inhibitors in the umbilical cord can be detected, is yet to be dis-
covered. The EULAR taskforce recommends stopping Inﬂiximab and
Adalimumab treatment at 20 weeks of gestation and Etanercept at
3032 weeks of pregnancy . The EULAR taskforce advises that the
use of Certolizumab throughout the whole pregnancy is safe [14].
Due to a lack of safety data, the use of Golimumab is not advised dur-
ing pregnancy [14].When taking all data together no increased risk of congenital
malformations in infants exposed to TNF inhibitors was found,
and most importantly no speciﬁc pattern of malformations could
be observed [17].
Vinet et al. showed in a large sample size, using the US claim data,
no excess risk of serious infections after in utero exposure to anti-
TNF biologic treatment [18].
Safety data on other biologic agents such as Tocilizumab, Ana-
kinra, Abatacept, Tofacitinib and Rituximab is not sufﬁcient enough
and the use of these agents is not advised during pregnancy [14].
Disease activity after stopping anti-TNF during pregnancy
There is only limited data available on the effect of stopping anti-
TNF treatment on disease course in pregnant patients. Most literature
suggests that stopping TNF inhibitors just before or during a preg-
nancy results in a ﬂare during pregnancy or in the peri- and postpar-
tum period. Contrary, F€orger et al. showed that in patients with
inactive disease, discontinuing TNF inhibitors before the 20th week
of gestation did not result in active disease later in pregnancy [19].
However, it should be noted that in this study patientreported out-
come measures were used to asses disease activity and that the value
of these measures during pregnancy are still point of discussion.
Vaccination after exposition to anti-TNF in utero
Infants who are exposed in the 2nd or 3rd trimester of pregnancy
to anti-TNF treatment should not receive live attenuated vaccines in
their ﬁrst 6 months of life [14]. Infants who are exposed to anti-TNF
treatment before the 22nd week of gestation can get vaccinated,
including live vaccines, conform the standard vaccine protocols [14].
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tors in utero.
Cheent et al. presented a case where vaccination at 3 months
resulted in a severe and lethal Bacillus Calmette Guerin (BCG) infec-
tion after in utero exposition to inﬂiximab [20]. Other studies found
only mild reactions to the administration of live vaccines in the ﬁrst
months of life after exposure to anti-TNF in utero.
Breastfeeding and anti-TNF
Breastfeeding during the use of TNF inhibitors Inﬂiximab, Adali-
mumab, Etanercept, and Certolizumab is appropriate; minimal trans-
fer of the TNF inhibitor into breast milk occurs [14].
Conclusion
Fertility is impaired in woman with RA, this is related to both the
disease itself as well as medication use. Pregnancy outcomes are
slightly impaired in women with RA and this is associated with dis-
ease activity. Tight disease control during pregnancy and in the post-
partum period for patients with active disease is advised to limit
complications.
Disease activity of RA improves during pregnancy, however a sub-
stantial percentage of women with RA has active disease during preg-
nancy and therapeutic interventions are required. Fortunately,
accumulating evidence shows the safety of many medications includ-
ing TNF inhibitors before and during pregnancy.
Challenges remain: although a treat-to-target approach is advised
during pregnancy, the feasibility of such an approach has never been
studied. In addition, it is unknown whether fertility outcomes and
pregnancy outcomes are comparable with healthy controls when
patients are in clinical remission. More information is needed on the
safety of vaccination with live attenuated vaccines on infants exposed
to anti-TNF in utero and the consequences of stopping anti-TNF dur-
ing pregnancy. Answers to these questions are expected from large
prospective cohorts and European collaborations.
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